Home
/
CytomX Therapeutics, Inc.
/
Financials
/
Quarterly
CytomX Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CytomX Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.96M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$18.66M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$50.92M
May 12, 2025
Q3
2025
Sep 30, 2024
$33.43M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$25.12M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$41.46M
May 12, 2025
Q3
2024
Sep 30, 2023
$26.38M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$24.72M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$23.50M
May 8, 2024
Q3
2023
Sep 30, 2022
$11.15M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$12.85M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$9.04M
May 9, 2023
Q3
2022
Sep 30, 2021
$17.59M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$16.29M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$15.97M
May 5, 2022
Q3
2021
Sep 30, 2020
$17.79M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$16.61M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$49.59M
May 6, 2021
Q3
2020
Sep 30, 2019
$10.71M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$9.01M
Aug 6, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.96M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$18.66M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$50.92M
May 12, 2025
Q3
2025
Sep 30, 2024
$33.43M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$25.12M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$41.46M
May 12, 2025
Q3
2024
Sep 30, 2023
$26.38M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$24.72M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$23.50M
May 8, 2024
Q3
2023
Sep 30, 2022
$11.15M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$12.85M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$9.04M
May 9, 2023
Q3
2022
Sep 30, 2021
$17.59M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$16.29M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$15.97M
May 5, 2022
Q3
2021
Sep 30, 2020
$17.79M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$16.61M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$49.59M
May 6, 2021
Q3
2020
Sep 30, 2019
$10.71M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$9.01M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($14.23M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($154.0K)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($154.0K)
Nov 6, 2025
Q1
2025
Mar 31, 2025
$23.53M
May 12, 2025
Q2
2025
Mar 31, 2025
$23.53M
Aug 7, 2025
Q3
2025
Mar 31, 2025
$23.53M
Nov 6, 2025
Q3
2025
Sep 30, 2024
$5.74M
Nov 6, 2025
Q3
2025
Jun 30, 2024
($6.53M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($6.53M)
Aug 7, 2025
Q2
2025
Mar 31, 2024
$13.79M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$13.79M
May 12, 2025
Q3
2025
Mar 31, 2024
$13.79M
Nov 6, 2025
Q3
2024
Sep 30, 2023
$2.99M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($1.09M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($1.09M)
Nov 7, 2024
Q3
2024
Mar 31, 2023
($3.31M)
Nov 7, 2024
Q2
2024
Mar 31, 2023
($3.31M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($3.31M)
May 8, 2024
Q3
2023
Sep 30, 2022
($29.06M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($29.50M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.77M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($1.29M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
$22.62M
May 12, 2025
Q3
2025
Sep 30, 2024
$4.11M
Nov 6, 2025
Q2
2025
Jun 30, 2024
($8.45M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
$11.66M
May 12, 2025
Q3
2024
Sep 30, 2023
$3.12M
Nov 7, 2024
Q2
2024
Jun 30, 2023
($3.35M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($5.65M)
May 8, 2024
Q3
2023
Sep 30, 2022
($29.71M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($30.05M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($32.06M)
May 9, 2023
Q3
2022
Sep 30, 2021
($22.64M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($19.21M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($15.63M)
May 5, 2022
Q3
2021
Sep 30, 2020
($14.90M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($16.14M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($2.79M)
May 6, 2021
Q3
2020
Sep 30, 2019
($25.72M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($31.23M)
Aug 6, 2020